As per MRFR analysis, the India Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at 6 (USD Million) in 2023. The India Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to grow from 10.5(USD Million) in 2024 to 150.3 (USD Million) by 2035. The India Non-Alcoholic Steatohepatitis Biomarkers Market CAGR (growth rate) is expected to be around 27.371% during the forecast period (2025 - 2035)
Key India Non-Alcoholic Steatohepatitis Biomarkers Market Trends Highlighted
The India Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is being driven by an increasing prevalence of obesity and metabolic syndrome in the region. The Indian government's initiatives for health awareness, such as the National Health Mission, have emphasized the importance of preventive healthcare, which extends to the early diagnosis of conditions like NASH. As lifestyle diseases become more common, the demand for effective biomarkers to diagnose and monitor liver health is rising.
Additionally, advancements in medical technology and increased investment in healthcare infrastructure provide opportunities for the development of innovative diagnostic tools and treatments for NASH.Recent trends indicate a growing interest from pharmaceutical companies in research and development focused on NASH biomarkers. This interest is bolstered by the increasing recognition of NASH as a significant public health issue in India, with better diagnostics potentially leading to improved treatment pathways. Expanding collaborations between research institutions and the biotech industry are also notable trends.
This collaboration aims to validate new biomarkers and create targeted therapies, driving market growth. Opportunities exist for health professionals and organizations to enhance education and awareness around NASH, thus fostering a proactive approach to liver health among the Indian population.Furthermore, as the population ages and urbanization increases, there is a potential to expand the market for NASH biomarkers through greater access to healthcare services. Overall, the India Non-Alcoholic Steatohepatitis Biomarkers Market is evolving, with various dynamics and trends shaping its future landscape.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
India Non-Alcoholic Steatohepatitis Biomarkers Market Drivers
Rising Prevalence of Obesity in India
One of the main causes of the increase in Non-Alcoholic Steatohepatitis (NASH) patients is obesity. Approximately 135 million persons in India were categorized as overweight or obese in 2019, according to the Global Burden of Disease research, which shows that the incidence of obesity has quadrupled over the previous 20 years. There is a significant need for non-alcoholic steatohepatitis biomarkers in the India non-alcoholic steatohepatitis biomarkers market industry due to the rising trend in obesity, which is directly correlated with increased incidences of NASH. New diagnostic techniques in the NASH biomarker arena will probably be encouraged, and more research and development investments will be made as long as healthcare organizations like the Indian Council of Medical Research (ICMR) continue to draw attention to the burden of metabolic illnesses.
Growing Awareness and Screening for Liver Diseases
The increasing awareness regarding liver diseases, including NASH, is another key driver for the India Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Recent initiatives by the Ministry of Health and Family Welfare in India, which underscore the importance of screening for liver health, are encouraging regular health check-ups. This regulatory focus on early detection is anticipated to boost the demand for reliable biomarkers to monitor liver health effectively.Furthermore, public campaigns led by organizations like the Hepatitis Foundation of India have ramped up screening efforts, resulting in an uptick of approximately 30% in liver-related health check-ups since 2021.
Increase in Healthcare Spending
There has been a significant increase in healthcare spending in India, which supports the growth of the Non-Alcoholic Steatohepatitis biomarkers segment. As per the National Health Mission reports, India has pledged to increase its healthcare expenditure to 2.5% of the Gross Domestic Product (GDP) by 2025. This funding is likely to lead to the development and implementation of advanced diagnostic technologies for NASH. With important entities such as the World Health Organization advocating for improved health infrastructure, the infusion of funds can catalyze growth in the India Non-Alcoholic Steatohepatitis Biomarkers Market, enabling more organizations to research and commercialize their biomarkers.
India Non-Alcoholic Steatohepatitis Biomarkers Market Segment Insights
Non-Alcoholic Steatohepatitis Biomarkers Market Type Insights
The India Non-Alcoholic Steatohepatitis Biomarkers Market is witnessing considerable advancement due to the rising incidences of liver diseases and the increasing awareness regarding non-alcoholic fatty liver disease among the population. The market is segmented Type wise into various categories, each contributing significantly to the overall landscape of the industry. Hepatic Fibrosis Biomarkers play a critical role in assessing the degree of fibrosis in patients, allowing healthcare professionals to evaluate the progression of liver damage more accurately.This segment has gained prominence due to its ability to predict adverse liver-related outcomes, making it essential for timely intervention and management.
Similarly, Serum Biomarkers are significant in this market as they offer a non-invasive means to monitor liver health and assess the presence and severity of non-alcoholic steatohepatitis. The convenience and efficiency of serum testing make it a preferred choice among clinicians, thus elevating its impact on diagnostics. Oxidative Stress Biomarkers underscore the importance of cellular damage assessment in the context of non-alcoholic steatohepatitis, as they are directly linked with the pathophysiological mechanisms of the disease.In India, rising oxidative stress levels due to lifestyle factors have made this segment pivotal in contemporary research.
Apoptosis Biomarkers are also noteworthy, as they relate to programmed cell death mechanisms, which have significant implications in liver diseases. Understanding apoptosis can help in determining the efficacy of treatments and assessing disease progression. Finally, the 'Others' category encompasses a range of emerging biomarkers that cater to specific research needs and diagnostic requirements, addressing niche areas that could provide extensive insights into non-alcoholic steatohepatitis.These diverse Types within the market collectively drive innovation, research, and improved patient outcomes in the context of liver health management, resonating with the expanding healthcare framework in India.
The overall growth dynamics of the India Non-Alcoholic Steatohepatitis Biomarkers Market reflect a burgeoning demand for effective diagnostics and interventions, thus highlighting the critical nature of market segmentation in shaping future healthcare strategies.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Non-Alcoholic Steatohepatitis Biomarkers Market End User Insights
The India Non-Alcoholic Steatohepatitis Biomarkers Market is significantly influenced by its End User segment, which comprises various entities that play crucial roles in the assessment and treatment of this condition. Research Institutes and Academics are pivotal in advancing understanding and driving innovations in biomarkers, thus contributing to their development and validation. Diagnostic Centres are essential as they facilitate early detection and monitoring, allowing for timely therapeutic interventions. Pharmaceutical Companies and Contract Research Organizations (CROs) are key players engaging in the development of novel medications and conducting clinical trials, which are necessary for bringing effective solutions to market.
Hospitals and Clinics serve a critical function, offering comprehensive care and treatment services, making them a vital point of contact for patients diagnosed with the condition. Other entities, which may include regulatory and health policy organizations, are also crucial as they shape market frameworks critical for the deployment of biomarkers in healthcare settings. This diversity within the End User segment highlights the collaborative effort needed to tackle Non-Alcoholic Steatohepatitis in India and underscores the growing importance of biomarkers in patient management and treatment outcomes.Collectively, these insights highlight the growth potential in the India Non-Alcoholic Steatohepatitis Biomarkers Market driven by increasing prevalence and awareness associated with this disease.
India Non-Alcoholic Steatohepatitis Biomarkers Market Key Players and Competitive Insights
The India Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market has been experiencing significant growth, driven by the increasing prevalence of obesity, diabetes, and metabolic syndrome, which heighten the demand for effective diagnostic solutions. In this rapidly evolving landscape, several key players are vying for market share by developing innovative biomarkers that enhance the detection, diagnosis, and characterization of NASH. The competitive dynamics of this market reveal a robust interplay between established pharmaceutical companies, emerging biotech firms, and diagnostic laboratories, contributing to advancements in research and technology.
As awareness of NASH rises among healthcare professionals and patients alike, the competition among stakeholders is expected to intensify, leading to a more diverse portfolio of products and services designed to meet the growing demands of this segment within India.Merck and Co has solidified its presence in the India Non-Alcoholic Steatohepatitis Biomarkers Market through its commitment to research and development, focusing on the exploration of biomarkers for liver diseases, including NASH. The company possesses strong capabilities in innovative drug development, which enhance its ability to produce effective biomarkers and diagnostic tools tailored for the Indian population.
Its established relationships with healthcare professionals and institutions in India further bolster its market position. Additionally, Merck and Co's comprehensive understanding of metabolic diseases allows it to integrate significant scientific expertise into the development of its product offerings, thereby catering to the unique needs of Indian patients and contributing to enhanced diagnostic accuracy in clinical practice.LabCorp has emerged as a notable player in the India Non-Alcoholic Steatohepatitis Biomarkers Market, offering a robust suite of diagnostic services and biomarker testing solutions.
The company has established itself through its extensive laboratory network across India, allowing for efficient sample processing and results delivery. LabCorp's strengths lie in its advanced analytical techniques and the development of specific assays for the detection of NASH, which aid clinicians in identifying and managing liver diseases effectively. Moreover, LabCorp's strategic partnerships and collaborations with local healthcare providers enhance its reach and service capabilities within the Indian market.
The company continues to invest in innovation and expand its offerings through mergers and acquisitions, positioning itself favorably to meet the rising demand for NASH biomarkers in India. By focusing on localized needs and continuously adapting to the evolving market landscape, LabCorp maintains a competitive edge in providing essential diagnostic services for the management of NASH.
Key Companies in the India Non-Alcoholic Steatohepatitis Biomarkers Market Include
India Non-Alcoholic Steatohepatitis Biomarkers Market Industry Developments
Recent developments in the India Non-Alcoholic Steatohepatitis Biomarkers Market indicate significant growth and interest from major companies such as Merck and Co, LabCorp, and Gilead Sciences. The market is seeing advancements in Research and Development efforts aimed at enhancing diagnostic capabilities for Non-Alcoholic Steatohepatitis (NASH). In August 2023, Merck and Co. announced strategic collaborations to accelerate biomarker discovery in liver diseases, which is expected to bolster their market position significantly. In addition, LabCorp's introduction of innovative testing solutions for NASH biomarkers has sparked interest among healthcare providers, addressing the rising prevalence of metabolic disorders in India.
The Indian government has emphasized the importance of early detection and management of liver diseases, further driving the market's growth. There have been no notable mergers or acquisitions among the specified companies in recent months. However, the ongoing focus on biomarker research is likely to lead to increased investments and partnerships, which will transform the landscape of the NASH biomarkers market in India. With rising health consciousness, the demand for effective testing solutions continues to surge, reflecting positively on the market dynamics and growth potential of key players.
India Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation Insights
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 6.0(USD Million) |
| MARKET SIZE 2024 | 10.5(USD Million) |
| MARKET SIZE 2035 | 150.3(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 27.371% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Merck and Co, LabCorp, Intercept Pharmaceuticals, Novartis, Alkermes, Gilead Sciences, Fujifilm Corporation, Genfit, Biocorp, Pfizer, HepQuant, Celerion, Quest Diagnostics, Cynapsus Therapeutics, Echosens |
| SEGMENTS COVERED | Type, End User |
| KEY MARKET OPPORTUNITIES | Rising prevalence of NASH, Increased demand for early diagnostics, Growing investment in research and development, Expanding biotechnology partnerships, Regulatory support for biomarker studies |
| KEY MARKET DYNAMICS | Increasing prevalence of obesity, Rising awareness of liver diseases, Advancements in biomarker technologies, Government initiatives and funding, Growing demand for early diagnosis |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Non-Alcoholic Steatohepatitis Biomarkers Market is expected to be valued at 10.5 million USD in 2024.
By 2035, the market is anticipated to reach a valuation of 150.3 million USD.
The market is projected to grow at a CAGR of 27.371 percent from 2025 to 2035.
Serum Biomarkers are expected to dominate the market with a valuation of 43.0 million USD by 2035.
The market value for Hepatic Fibrosis Biomarkers in 2024 is projected to be 2.1 million USD.
Some major players in the market include Merck and Co, LabCorp, Intercept Pharmaceuticals, and Novartis.
The market size for Apoptosis Biomarkers is anticipated to reach 21.0 million USD by 2035.
The increasing prevalence of non-alcoholic fatty liver disease is one of the emerging trends driving market growth.
Challenges faced by the market include regulatory hurdles and the need for advanced diagnostic technologies.
The market for Oxidative Stress Biomarkers is projected to reach a valuation of 34.0 million USD by 2035.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
